Author:
Chan Gordon Chun-Kau,Than Win Hlaing,Kwan Bonnie Ching-Ha,Lai Ka-Bik,Chan Ronald Cheong-Kin,Teoh Jeremy Yuen-Chun,Ng Jack Kit-Chung,Chow Kai-Ming,Fung Winston Wing-Shing,Cheng Phyllis Mei-Shan,Law Man-Ching,Leung Chi-Bon,Li Philip Kam-Tao,Szeto Cheuk-Chun
Abstract
AbstractThere were limited data on adipose and serum zinc alpha-2-glycoprotein (ZAG) expression and its association with body composition in patients with advanced chronic kidney disease (CKD). This study aimed to quantify adipose and serum ZAG expression and evaluate their association with body composition and its longitudinal change, together with mortality in incident dialysis patients. We performed a single-center prospective cohort study. Patients who were planned for peritoneal dialysis were recruited. ZAG levels were measured from serum sample, subcutaneous and pre-peritoneal fat tissue obtained during peritoneal dialysis catheter insertion. Body composition and functional state were evaluated by bioimpedance spectroscopy and Clinical Frailty Scale respectively at baseline and were repeated 1 year later. Primary outcome was 2-year survival. Secondary outcomes were longitudinal changes of body composition. At baseline, the average adipose and serum ZAG expression was 13.4 ± 130.0-fold and 74.7 ± 20.9 µg/ml respectively. Both adipose and serum ZAG expressions independently predicted adipose tissue mass (ATM) (p = 0.001, p = 0.008, respectively). At 1 year, ATM increased by 3.3 ± 7.4 kg (p < 0.001) while lean tissue mass (LTM) remained similar (p = 0.5). Adipose but not serum ZAG level predicted change in ATM (p = 0.007) and LTM (p = 0.01). Serum ZAG level predicted overall survival (p = 0.005) and risk of infection-related death (p = 0.045) after adjusting for confounders. In conclusion, adipose and serum ZAG levels negatively correlated with adiposity and predicted its longitudinal change of fat and lean tissue mass, whilst serum ZAG predicted survival independent of body mass in advanced CKD patient.
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Law, S. & Davenport, A. Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent peritoneal dialysis patients. Br. J. Nutr. 123(11), 1269–1276 (2020).
2. Choy, A.S.-M. et al. Weight change during the first year of peritoneal dialysis: Risk factors and prognostic implications. Hong Kong J. Nephrol. 17(2), 28–35 (2015).
3. Keane, D. et al. Changes in body composition in the two years after initiation of haemodialysis: A retrospective cohort study. Nutrients 8, 11 (2016).
4. Visser, W. J., Egmond, A., Timman, R., Severs, D. & Hoorn, E. J. Risk factors for muscle loss in hemodialysis patients with high comorbidity. Nutrients 12, 9 (2020).
5. Kalantar-Zadeh, K. et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am. J. Clin. Nutr. 83(2), 202–210 (2006).